跳至主要内容
临床试验/NCT06716593
NCT06716593已完成不适用

Trajectory of Body Composition Identifies Locally Advanced Gastric Cancer with Cachexia Following Neoadjuvant Chemotherapy (FJMUGS-2411)

Chang-Ming Huang, Prof.1 个研究点 分布在 1 个国家目标入组 600 人开始时间: 2024年9月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
600
试验地点
1
主要终点
3-year overall survival; 5-year overall survival

研究概览

简要总结

This longitudinal, multicentre cohort study included LAGC patients treated with NACT between 01/2010-12/2021. BC measurements including skeletal muscle mass (SMM) and total adipose tissue area (TATA) were evaluated by computed tomography at the third lumbar vertebra at baseline and follow-up imaging. Unsupervised latent class growth mixed models were applied to distinguish potential longitudinal SMM and TATA trajectories for identifying cachexia. The primary study endpoint was overall survival (OS), with secondary endpoints including Recurrence-free survival (RFS), objective response rate (ORR) and safety. Multiple Cox proportional hazards models were used to calculate adjusted hazard ratios (HRs) for survival.

详细描述

This is a retrospective, longitudinal, multicenter, real-world cohort study

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 84 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • (1) locally advanced gastric cancer (cT2-4NxM0) with clinical staging before neoadjuvant chemotherapy, (2) no history of other malignant tumors, (3) no evidence of distant metastasis or invasion of adjacent organs, and (4) patients who underwent radical gastrectomy following neoadjuvant chemotherapy.

排除标准

  • (1) history of gastric surgery; (2) acute cardiovascular disease (such as cerebrovascular or coronary artery injury) within the past three months; (3) emergency surgery; (4) active infection or severe systemic immunodeficiency; and (5) incomplete serological, computed tomography, or anthropometric data.

结局指标

主要结局

3-year overall survival; 5-year overall survival

时间窗: 3 years or 36 months; 5 years or 60months

Survival status at 3/5 years: survival, death, survival with tumor, deletion.

次要结局

未报告次要终点

研究者

发起方
Chang-Ming Huang, Prof.
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Chang-Ming Huang, Prof.

M.D. FACS

Fujian Medical University

研究点 (1)

Loading locations...

相似试验